- TANDUTINIB
-
-
2026-07-29
- CAS:228266-40-8
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- Taltobulin
-
- $15.00
-
2021-07-13
- CAS:228266-40-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Taltobulin
-
- $15.00
-
2021-07-09
- CAS:228266-40-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| | TANDUTINIB Basic information |
| Product Name: | TANDUTINIB | | Synonyms: | CS-1371;N,beta,beta-Trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-L-valinamide;Hti 286;L-Valinamide, N,beta,beta-trimethyl-L-phenylalanyl-N-((1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl)-N,3-dimethyl-;Spa 110;Unii-J6D6912bxs;N,β,β-Trimethyl-L-phenylalanyl-N-[(3S,4E)-5-carboxy-2-methyl-4-hexen-3-yl]-N,3-dimethyl-L-valinamide;Taltobulin (HTI-286) | | CAS: | 228266-40-8 | | MF: | C27H43N3O4 | | MW: | 473.66 | | EINECS: | | | Product Categories: | | | Mol File: | 228266-40-8.mol |  |
| | TANDUTINIB Chemical Properties |
| Melting point | 135-137 ºC | | Boiling point | 662.4±55.0 °C(Predicted) | | density | 1.063 | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMSO: 40 mg/ml | | form | A solid | | pka | 4.68±0.19(Predicted) | | color | White to off-white |
| | TANDUTINIB Usage And Synthesis |
| Uses | Treatment of solid tumors. | | in vivo | Taltobulin (HTI-286; 1.6 mg/kg i.v.) inhibits the growth of human tumor xenografts (e.g., HCT-15, DLD-1, MX-1W, and KB-8-5) in athymic nu/nu female mice[1].
Taltobulin (HTI-286; 3 mg/kg; p.o. gavage) inhibits growth by 97.3 % and 82% in athymic nu/nu female mice with Lox melanoma xenografts and KB-3-1 epidermoid xenograft model, respectively[1]. | Animal Model: | Athymic nu/nu female mice with Lox melanoma model (5-6 weeks of age)[1] | | Dosage: | 1.6 mg/kg | | Administration: | Administered i.v.;for 35 days | | Result: | Growth of Lox tumors was inhibited by 96-98% on day 12 compared with vehicle-treated controls.
Growth of KB-8-5 tumors was inhibited by 84% on day 14 compared with vehicle-treated controls.
Growth of MX-1W tumors was inhibited by 97% compared with vehicle-treated controls.
Growth of DLD-1 and HCT-15 tumors was inhibited by 80 and 66%, respectively. |
| | IC 50 | Traditional Cytotoxic Agents |
| | TANDUTINIB Preparation Products And Raw materials |
|